As methicillin-resistant Staphylococcus aureus (MRSA) becomes more prevalent, vancomycin is becoming increasingly used as a prophylaxis against surgical-site infections for cardiothoracic surgeries. However, vancomycin administration can be challenging, and the pharmacokinetics of alternative antibiotics in this setting are poorly understood. The primary objective of this investigation was to describe the pharmacokinetics of daptomycin in patients undergoing coronary artery bypass graft surgery. We enrolled 15 patients undergoing coronary artery bypass surgery requiring cardiopulmonary bypass. Each subject was administered a single open-label dose of daptomycin (8 mg/kg of body weight) for surgical prophylaxis. Fourteen daptomycin plasma samples were collected. Safety outcomes between subjects who received daptomycin and 15 control subjects who received the standard-of-care antibiotic were compared. The mean maximal concentration of daptomycin (C max ) was 84.4 ؎ 27.1 g/ml; the mean daptomycin concentration during the cardiopulmonary bypass procedure was 33.2 ؎ 11.4 g/ml and was 30.9 ؎ 12.7 g/ml at sternum closure. Mean daptomycin concentrations at 12, 18, 24, and 48 h were 22.7 ؎ 9.7, 16.2 ؎ 8.2, 12.0 ؎ 4.7, and 3.5 ؎ 2.3 g/ml, respectively. Mean daptomycin concentrations were consistently above the MIC at which 90% of the tested isolates are inhibited (MIC 90 ) for S. aureus and S. epidermidis during the cardiopulmonary bypass procedure. Daptomycin was not associated with surgical-site infections or differences in adverse events compared to findings for control subjects. We found that a single dose of daptomycin at 8 mg/kg was well tolerated and achieved adequate plasma concentrations against common pathogens associated with surgical-site infections after cardiothoracic surgery. Daptomycin may be considered an alternative surgical prophylaxis antibiotic for patients undergoing cardiothoracic bypass surgery who are unable to receive vancomycin.
Surgical-site infections (SSIs) are the second most common cause of health care-acquired infections (22) . A Centers for Disease Control and Prevention report from 2002 estimated that 274,098 SSIs occur annually in the United States (22) . Staphylococcus aureus and coagulase-negative staphylococci (CoNS) are the most common pathogens associated with SSIs in clean surgeries (2, 15, 18, 44) , and knowledge of an antibiotic's MIC against these pathogens is important. SSIs in patients undergoing coronary artery bypass graft (CABG) surgery have been reported between 3.5 and 7.4% (12, 42, 47) . Among CABG-associated SSIs, S. aureus causes 30 to 68% of infections, and methicillin-resistant S. aureus (MRSA) is found in 10 to 23% of infections (12, 14, 16, 42) . Antibiotic prophylaxis is a critical component of SSI prevention (5) .
One of the most commonly performed major surgeries in the United States and worldwide is CABG surgery with cardiopulmonary bypass (CPB) (26) . SSIs complicating this procedure result in significant morbidity, mortality, and health care expenditures (14, 16) . For patients undergoing cardiothoracic surgery, current guidelines recommend the administration of cefazolin for surgical antibiotic prophylaxis and vancomycin if the patient is at high risk for MRSA or has a ␤-lactam allergy (5) . However, no definition of high risk is given. A recent investigation suggested that if MRSA prevalence in a given medical center exceeds 3%, glycopeptide prophylaxis in patients undergoing cardiothoracic surgery would minimize SSIs better than ␤-lactam prophylaxis (34) . Vancomycin, therefore, may be warranted at many, if not all, institutions in the United States, given that MRSA prevalence among S. aureus strains typically is greater than 60% (23, 35) .
While vancomycin often is warranted for surgical prophylaxis in cardiothoracic surgery, not all patients can tolerate vancomycin. The rapid administration of vancomycin can lead to "red man syndrome" and hypotension, and thus it requires a 60-min infusion. Additionally, vancomycin is recommended to be given 2 h prior to surgical incision (5) . Because there may be little advanced notice before a surgical procedure's start time, vancomycin administration can be problematic. Vancomycin's potential for nephrotoxicity also may deter many physicians from its use in patients at risk for cardiopulmonary bypass-associated renal insufficiency (43) . Alternative agents used often have activity against methicillin-susceptible S. aureus (MSSA) but no activity against MRSA or have little or no data supporting their use as surgical prophylaxis (43) . Currently, there is no recommended alternative for patients undergoing surgery who are unable to tolerate vancomycin and are at risk for a MRSA SSI.
Daptomycin, which has activity against MRSA strains, cur-rently is approved for the treatment of S. aureus skin and skin structure infections, bacteremia, and right-sided endocarditis (6, 40) . The daptomycin MIC at which 90% of tested S. aureus and CoNS isolates are inhibited (MIC 90 ) ranges from 0.5 to 1 g/ml (3, 7, 41) , and the susceptible breakpoint against S. aureus is set at a MIC of Յ1 g/ml (9) . Daptomycin has a relatively long half life (8 h) (9) . Daptomycin is effective against infections caused by common SSI pathogens, is well tolerated, and can be administered more rapidly (usually taking 30 min) than vancomycin. However, there are no data on its plasma concentrations during CABG surgery with CPB. Many physiologic changes occur during CPB that may result in the alteration of the pharmacokinetics of medications, including antibiotics (4, 13, 17, 21, 29, 32, 38, 39) . The pharmacokinetics of any antibiotic during CPB must be evaluated, since factors such as hemodilution, protein binding, and the sequestration of the drug by the CPB apparatus during CPB have been known to alter drug concentrations (17, 24, 29, 39) . Therefore, we designed and conducted a prospective investigation to determine the pharmacokinetic parameters of daptomycin given as surgical prophylaxis for patients undergoing CABG surgery with CPB.
MATERIALS AND METHODS
Study population. From July 2008 to August 2010, we recruited subjects undergoing CABG surgery at Harbor-UCLA Medical Center, a 400-bed tertiarycare county hospital. Several pharmacokinetic studies of adult patients undergoing CABG with CPB included 5 to 13 subjects (1, 4, 13, 21, 24, 25, 30-33, 38, 45) . Thus, to have a robust sample size, we chose to enroll 15 subjects in the daptomycin group to determine the pharmacokinetics of the drug. Additionally, as a control group against which we could compare adverse events, we planned to prospectively enroll 15 subjects who received the standard-of-care surgical prophylaxis at our center (vancomycin or cefazolin).
Patients were eligible if they met the following inclusion criteria: (i) undergoing CABG surgery and CPB without valve replacement, (ii) between 18 and 75 years of age, (iii) body mass index (BMI) between 18.5 kg/m 2 and 39.9 kg/m 2 , (iv) creatinine clearance (CL) of Ն50 ml/min based on the Cockcroft Gault equation (8) , (v) no known active or suspected infection, and (vi) negative pregnancy test (for women of childbearing age). Patients were excluded if they (i) had a history of allergic reaction to daptomycin or components of daptomycin, (ii) had received daptomycin within 7 days prior to the surgery, (iii) had a baseline creatine phosphokinase (CPK) level greater than three times the upper limit of normal, (iv) had a history of myopathy or complaints consistent with myopathy, or (v) were pregnant and/or breast feeding.
Written consent was obtained from each subject. Subjects who received daptomycin were compensated. Investigational Review Board approval was obtained from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and Western University of Health Sciences.
Plasma daptomycin concentrations. Subjects who agreed to receive daptomycin as a surgical prophylaxis received a single intravenous administration of 8 mg/kg of body weight of daptomycin 30 to 60 min prior to incision. An 8-mg/kg dose of daptomycin was chosen due to concerns that drug concentrations might be lowered during CPB procedures. Blood samples were drawn from an arterial line or the bypass machine during the surgery and from a venous catheter after the arterial catheter was removed. A total of 14 blood samples were collected at predetermined time points (Table 1) . After collection, blood samples were centrifuged and plasma samples were separated and frozen at Ϫ20°C. Plasma samples then were shipped in batches and daptomycin concentrations were determined by an independent laboratory at Hartford Hospital (CT). All samples were shipped in a blinded fashion so that those performing the analysis did not know each specimen's collection time or the subject. Total plasma daptomycin concentrations were determined by utilizing standard high-performance liquid chromatography (HPLC) techniques as described elsewhere (10) . Plasma concentrations were compared to the daptomycin MIC 90 against the common pathogens involved in SSIs, specifically Staphylococcus aureus and Staphylococcus epidermidis.
Pharmacokinetic analysis.
The pharmacokinetic analysis of daptomycin among patients undergoing CABG surgery with CPB was performed using the noncompartmental method. The maximal concentration of daptomycin (C max ) in plasma for each subject was used to calculate the mean C max of daptomycin in our study population and was compared to previously reported data from healthy volunteers (46) . The area under the concentration-time curve from 0 h to infinity (AUC 0-ϱ ) among patients undergoing CPB surgery was calculated by the linear trapezoidal method with the area from the last time point to infinity being estimated by C last / z , where z represented the terminal elimination rate constant and was obtained by least-square regression analysis using terminal data points.
The terminal elimination half-life (t 1/2,z ), total systemic clearance (CL), and apparent volume of distribution (V z ) among patients undergoing CABG surgery with CPB were determined. t 1/2,z and CL were calculated as 0.693/ z and dose/ AUC 0-ϱ , respectively. V z was obtained by dividing CL by z . The half-life, CL, V z , AUC, and protein binding (PB) parameters in our study were compared to those from healthy volunteers to determine the effect of CPB on the pharmacokinetics of daptomycin (11, 46) . Safety monitoring. To evaluate possible complications of daptomycin, such as myositis, a baseline CPK level was checked prior to surgery and monitored daily until hospital discharge. Additionally, CPK-myocardial band (MB), complete blood counts, serum creatinine, and liver function tests (aspartate aminotransferase [AST] and alanine transaminase [ALT]) were collected preoperatively and postoperatively (on a daily basis until hospital discharge) to assess safety. The surgical sites also were assessed daily until hospital discharge to identify any signs and symptoms of SSIs (e.g., purulent drainage, pain or tenderness, localized redness, swelling, or heat) (27) . Identical safety monitoring was performed for control subjects. Finally, a review of the subject's medical record was conducted to determine if any SSIs developed during the 30-day follow-up, and subjects were called 30 days after surgery to determine if any signs or symptoms of SSIs appeared after hospital discharge.
Data analysis. Analysis comparing baseline characteristics and daily labs of the subjects who received daptomycin to those of subjects who received the standardof-care antibiotic were conducted using SAS v9.1.3 (Cary, NC). t test, chi-square test, and Fisher's exact method were used when appropriate to determine differences between groups. P Ͻ 0.05 was considered statistically significant. The trial was registered at ClinicalTrials.gov (identifier NCT00701636).
RESULTS
Treating clinicians referred 54 patients undergoing CABG with CPB. All were approached to participate in the study, and 32 agreed to participate. Patients were excluded for the following reasons: 15 declined to participate, 2 were greater than 75 years of age, 2 patients had a BMI greater than 40 kg/m 2 , and 3 had a creatinine clearance of lower than 50 ml/min. Two subjects consented and then had their surgery cancelled, and the final number of subjects in the daptomycin and control groups was 15 each. Subjects who received daptomycin had demographics, baseline laboratory values, and comorbidities similar to those of control subjects (Table 2) except for BMI;, control subjects had a higher BMI than subjects receiving daptomycin (31 Ϯ 6.6 and 26.4 Ϯ 4.4, respectively; P ϭ 0.03). All subjects in both study groups were first-time CABG patients with the left internal mammary artery and saphenous vein grafted. The average number of grafts was three in both study groups.
Among the 15 subjects receiving daptomycin, the average infusion time was 43 min. Due to commonly occurring modest delays in surgery or surgery starting slightly sooner than scheduled, the time from the end of infusion to the time of incision was greater than 60 min for three subjects and less than 30 min for three subjects who received daptomycin. The infusion of daptomycin was completed prior to the time of incision for all subjects. All patients in the daptomycin study group received one additional postoperative dose of vancomycin.
Among the standard-of-care study group, 14 subjects received vancomycin and 1 subject received cefazolin. The typical dose of vancomycin or cefazolin given as prophylaxis was 1 g. Thirteen subjects in the standard-of-care arm received one additional postoperative dose of vancomycin.
Pharmacokinetic profiles for all subjects are overlaid in Fig.  1 . For a clearer display, representative daptomycin concentration profiles for the period of 0 to 10 h from subject 1 are shown in Fig. 2 . Following the administration of a single dose of daptomycin at 8 mg/kg, the mean C max of daptomycin was 84.4 Ϯ 27.1 g/ml (Table 3 ). The mean daptomycin concentration prior to the initiation of the CPB procedure was 54.6 Ϯ 21.2 g/ml. The mean daptomycin concentrations at 5, 30, and 60 min after CPB was initiated were 28.3 Ϯ 16.6, 35.0 Ϯ 12.4, and 34.3 Ϯ 16 g/ml, respectively. One subject sample was excluded from the 60-min sample time following the initiation of CPB because the CPB procedure lasted 49 min. The mean daptomycin concentrations were 33.2 Ϯ 11.4 g/ml during the entire CPB procedure ( Table 3 ). The mean daptomycin concentration was 34.4 Ϯ 11.2 g/ml at approximately 5 min following aortic declamping and 30.9 Ϯ 12.7 g/ml at sternum closure, and at 12, 18, 24, and 48 h the concentrations were 22.7 Ϯ 9.7, 16.2 Ϯ 8.2, 12.0 Ϯ 4.7, and 3.5 Ϯ 2.3 g/ml, respectively ( Table 3) .
The mean daptomycin AUC 0-ϱ was 877.8 Ϯ 312.2 g ⅐ h/ml. Mean daptomycin concentrations were consistently above the MIC 90 against S. aureus and CoNS during the CPB procedure and throughout the surgery. The mean terminal elimination half-life (t 1/2,z ) of daptomycin was found to be 13.8 Ϯ 3.9 h, the total clearance (CL) was found to be 10.8 Ϯ 5.2 ml/h/kg, and the apparent volume of distribution (V z ) was found to be 0.21 Ϯ 0.1 liter/kg among patients undergoing CABG surgery with CPB. Protein binding samples were available for nine daptomycin subjects. The mean protein binding levels at sample time 3 (at the time of incision of the sternum), sample time 8 (at the time of aortic declamping), and sample time 11 (12 h after the beginning of daptomycin infusion) were 84.2 Ϯ 5.1, 81.5 Ϯ 2.2, and 79.0 Ϯ 1.6%, respectively.
During hospitalization and the 30-day follow-up period, no subject that received daptomycin had signs or symptoms of SSIs, and three control subjects developed a possible or definite SSI. These three control subjects received one additional dose of vancomycin (1 g) postoperatively. Of these three subjects, one was rehospitalized 22 days after CABG for the management of a sternal wound infection, another was rehospitalized 17 days after the CABG surgery for a left thigh wound dehiscence, which was not thought to be infectious (although infection could not be ruled out), and another subject was treated in the outpatient setting for leg cellulitis at the vein harvest site 13 days after their CABG surgery. All three subjects recovered without sequelae. Regarding other adverse events, we did not find any clinical signs or symptoms of myositis among subjects who received daptomycin. In terms of biochemical evidence of myositis, elevated CPK and CK-MB levels occurred in both subject groups, levels decreased over time, and there were no significant differences in CPK levels between groups at any time point (Table 4 ). All other surveyed laboratory parameters (Table 2) did not differ significantly postoperatively between groups at any time point (data not shown). Four noninfectious serious adverse events occurred in subjects. Three (one in the daptomycin arm and two in the control group) returned to the operating room the evening of the surgery due to bleeding, and after the reexploration of the mediastinum the bleeding resolved. All recovered without sequelae. One control subject expired 3 days after surgery due to ventricular tachycardia.
DISCUSSION
Our study is one of the largest investigations (n ϭ 15) examining the pharmacokinetics of an antibiotic during CABG and CPB (1, 4, 13, 21, 24, 25, 30-33, 38, 45) . We found that after the administration of a single 8-mg/kg dose of daptomycin to patients undergoing CABG surgery, mean daptomycin plasma concentrations exceeded the MIC 90 against common pathogens that cause SSIs in this population. Among subjects receiving daptomycin, the drug was well tolerated.
In terms of pharmacokinetics, when daptomycin was given to healthy subjects between 18 and 45 years of age, a single dose of 6 mg/kg resulted in a mean C max of 82 g/ml and mean t 1/2 of 8 h (46). While we gave a higher dose of daptomycin at 8 mg/kg that resulted in a mean daptomycin C max of 84.4 g/ml and mean half-life of 13.8 h, our single-dose study consisted of a different study population with subjects undergoing a CABG surgery and CPB procedure and were between 41 and 71 years of age. The mean daptomycin concentration was lowest 5 min after the initiation of the CPB procedure at 28.3 Ϯ 16.6 g/ml, and the mean daptomycin concentration obtained approximately 5 min following the CPB procedure was 34.4 Ϯ 11.2 g/ml. These findings are consistent with other pharmacokinetic studies evaluating antibiotic concentrations (e.g., vancomycin and cefazolin) during CPB procedures, in which factors such as hemodilution caused acute decreases in concentration shortly after the initiation of CPB and overall decreases in drug concentrations during CPB (13, 21, 31, 37) . Based on our findings, the CPB procedure did alter daptomycin concentrations; however, the mean daptomycin concentrations were consistently at least 10 times above the reported MIC 90 against S. aureus and CoNS during the CPB procedure and during the entire surgery. While the CL of daptomycin in our study was similar to those previously reported for healthy volunteers, protein binding was lower, the volume of distribution was larger, and the half-life was prolonged in our investigation (46) . It is known that CPB may cause alterations in protein binding in drugs that are highly protein bound (such as daptomycin) because of potential competitive protein binding with heparin and hemodilution with the prime pump volume, and bypass can cause the denaturation of the proteins (29, 39) . We postulate that the lower protein binding allowed for more free active drug to be available, resulting in the expanded volume of distribution and thus prolonged half-life in our subjects undergoing CABG surgery with CPB.
Current guidelines by the Surgical Infection Prevention Guidelines Writers Workgroup recommend that the duration of antibiotic prophylaxis should not exceed 24 h after surgery (5) . Antibiotic surgical prophylaxis requires one dose prior to the surgical procedure and may require the administration of an additional dose if there is significant blood loss or if the duration of the surgery exceeds two times the antibiotic's half life (5) . Given the long half life of daptomycin in our study, daptomycin may have some practical advantages over vancomycin, in that redosing would almost never be required unless the procedure was extraordinarily prolonged. Mean concn during CPB (g/ml)
Concn at sternum closure (g/ml) In terms of daptomycin's tolerability, we found no evidence of differential rates of adverse effects between subjects on daptomycin and the standard-of-care antibiotic, although the sample size for detecting adverse events was relatively small. Although all subjects in the daptomycin group were on statins, we found no evidence of toxicity of daptomycin, specifically myositis or elevated CPK levels, which have been reported with prolonged daptomycin administration. Additionally, while CPK and CK-MB levels were elevated following the surgery, there were no differences in the two study arms. Notably, both CPK and CK-MB values were on a downward trend by hospital discharge (postoperative day 6) compared to the values from postoperative day 1.
Our investigation had several strengths. First, this study is the first to examine a newer agent with broad-spectrum activity against Gram-positive organisms (including MRSA) and demonstrated that despite the swings in antibiotic concentration that occur during CPB, antibiotic concentrations appear sufficient to kill potential pathogens. Older antibiotics (e.g., trimethoprim-sulfamethoxazole, clindamycin, and doxycycline) that generally have activity against community-associated MRSA strains are not considered reliably active against circulating health care-acquired MRSA strains (28, 36) . Additionally, these older antibiotics (e.g., trimethoprim-sulfamethoxazole) have not been studied in the setting of CPB, hence their pharmacokinetics and appropriateness during CPB are unknown (20) . Second, we found no evidence that daptomycin was associated with increased toxicity compared to levels for prospectively enrolled controls. Third, our sample size of 15 subjects for patients undergoing CPB was relatively large and more robust than those of most other antibiotics studied during CPB, such as vancomycin, cefazolin, cephalothin, and ciprofloxacin (1, 4, 13, 21, 24, 25, 30-33, 38, 45) .
There are limitations to our investigation. First, despite its relatively large size for a pharmacokinetic study during CPB, our study was not powered to determine efficacy and safety in terms of SSIs and other adverse effects. It is noteworthy that most investigations of antibiotic pharmacokinetics during CPB have 10 or fewer subjects (1, 4, 13, 21, 24, 25, (30) (31) (32) (33) 45) , so our investigation was relatively robust. Second, all subjects came from a single study site and may not represent patients at other centers or their surgical standards of practice. Nevertheless, our patients were diverse in terms of race, ethnicity, and BMI. Finally, we excluded patients undergoing valve replacement, as these patients may have a higher risk of SSI (19) . We chose to exclude this group, as we thought it prudent to establish adequate daptomycin pharmacokinetics in a group at lower risk for infection before examining a group in which the consequences of SSI could be severe. a All values (except P values) are given as means Ϯ standard deviations. While the daily postoperative laboratory studies were part of the study protocol, not all subjects received laboratory testing on all days. Additionally, the day of discharge varied and laboratory monitoring was not done after hospital discharge. Hence, the number of subjects undergoing laboratory monitoring decreased over time. POD, postoperative day. In summary, we described daptomycin pharmacokinetics after a single 8-mg/kg dose during CABG surgery and CPB procedure. Our findings suggest that plasma daptomycin concentrations constitute adequate antibiotic prophylaxis in this population. Larger studies evaluating daptomycin's efficacy at minimizing SSIs are warranted to validate its use as an effective antibiotic for surgical prophylaxis.
